Inactive Instrument

Ceapro Inc.

Equities

CZO

CA1499071076

Biotechnology & Medical Research

Ceapro Inc. : to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

January 11, 2021 at 08:19 pm IST

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ('Ceapro' or the 'Company'), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro will present at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021.

The video webcast presentation will be available for viewing on-demand beginning Monday, January 11, 2021, at 6:00 AM ET for those registered for the event and will be accessible on the IR Calendar page of the Investors section of the Company's website (www.ceapro.com) and will be archived for 90 days following the event.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and 'active ingredients' from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.

Contact:

Tel: +1 (833) 475-8247

Latest news about Ceapro Inc.

Aeterna and Ceapro Brief: Cos Complete Merger Transaction; New Name Expected to be Announced in Coming Weeks and Details of AGM Expected to be Announced Shortly	03/06	MT
Aeterna Zentaris Inc. completed the acquisition of Ceapro Inc. in a merger of equals transaction.	03/06	CI
Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger	29/05	MT
Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/05	CI
Aeterna Zentaris Finalizes Some Details for Ceapro Merger	17/05	MT
Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro	17/05	MT
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/04	CI
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/04	CI
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	28/03	MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	28/03	MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	27/03	MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	27/03	MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	27/03	MT
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co	26/02	MT
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	14/12	MT
Aeterna Zentaris and Ceapro Brief: Cos Announcing Merger of Equals to Create a Diversified Biopharmaceutical Co	14/12	MT
Ceapro Inc. Announces Dosing of First Patients In Phase 1-2a Study of Avenanthramides	13/12	MT
Ceapro Inc. Announces Commencement of Patient Dosing in its Phase 1-2a Study Evaluating its Product, Avenanthramides, for Potential Applications in Managing Conditions Related to Inflammation	13/12	CI
Ceapro Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11	CI
Ceapro Inc. Initiates Phase 1-2a Study Assessing Avenanthramides For Potential Applications in Inflammation Based Diseases	28/11	MT
Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases	27/11	CI
Aeterna Zentaris Inc. entered into a definitive agreement to acquire Ceapro Inc. for CAD 21.3 million in a merger of equals transaction.	09/11	CI
Ceapro Inc. Announces the Signing of A Technical Collaboration with NATEX Prozesstechnologie Gmbh to Accelerate the Scale-Up of Its Proprietary PGX Technology Towards Commercial Level	07/11	CI
Ceapro Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/23/29	CI
Ceapro Extends International Supply and Distribution Agreement with German Provider of Active Ingredients, Symrise	25/23/25	MT

Chart Ceapro Inc.

Duration

Period

More charts

Company Profile

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

Sector

Biotechnology & Medical Research

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+22.15%	4.66TCr
LONZA GROUP AG	+45.94%	4.17TCr
IQVIA HOLDINGS INC.	-2.37%	4.12TCr
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	3.24TCr
CELLTRION, INC.	-6.35%	2.81TCr
ICON PUBLIC LIMITED COMPANY	+20.42%	2.82TCr
UNITED THERAPEUTICS CORPORATION	+48.83%	1.45TCr
MEDPACE HOLDINGS, INC.	+45.00%	1.37TCr
BIO-TECHNE CORPORATION	+0.06%	1.22TCr

Other Biotechnology & Medical Research